Publications by authors named "James S Graydon"

Pemphigus is a debilitating IgG-mediated autoimmune disease requiring better tolerated, more targeted, and rapid onset therapies. ALXN1830 is a humanized IgG4 antibody that blocks neonatal Fc receptor interactions with IgG. A multicenter, open-label safety and tolerability phase 1b/2 trial (NCT03075904) was conducted in North America from July 2017 to January 2019 and included patients aged ≥18 years with a confirmed diagnosis of pemphigus (vulgaris or foliaceus) and active disease.

View Article and Find Full Text PDF

Variants of the gene have been associated with a wide range of diseases. The present study analyzed data from clinical genotyping of and in 1405 patients in urban primary care settings. Striking differences in ethnogeographic frequencies of polymorphisms were observed.

View Article and Find Full Text PDF

A 44-year-old Caucasian woman presented with a history of empirical treatment with 20 pain and psychotropic medications, as well as dual comorbidity of intractable pain and depression. A multiple gain-of-function profile in the CYP450 family of cytochrome P450 (CYP450) drug metabolism isoenzymes was discovered. The patient was a homozygote of suprafunctional alleles for both CYP2D6 (35/35) and CYP2C19 (17/17) genes and functional alleles for CYP2C9 (1/1), which account for aggregate drug metabolism function at the upper 1% of the population.

View Article and Find Full Text PDF

We describe a population genetic approach to compare samples interpreted with expert calling (EC) versus automated calling (AC) for CYP2D6 haplotyping. The analysis represents 4812 haplotype calls based on signal data generated by the Luminex xMap analyzers from 2406 patients referred to a high-complexity molecular diagnostics laboratory for CYP450 testing. DNA was extracted from buccal swabs.

View Article and Find Full Text PDF